Latest news with #FlemmingOrnskov
Reuters
24-07-2025
- Business
- Reuters
Swiss skin care firm Galderma raises sales outlook for 2025, shares jump
ZURICH, July 24 (Reuters) - Swiss skin care company Galderma (GALD.S), opens new tab on Thursday raised its outlook for 2025 after posting net sales growth of 12.2% during the first six months, driven by double-digit growth in the United States and international markets. Galderma said it expected net sales growth at constant currency to be between 12% and 14% this year, up from previous guidance of 10-12%, as it confirmed guidance on its core EBITDA margin of around 23%, again at constant currency. The company, which floated on the Swiss stock exchange in March 2024, has seen its shares jump by over 140% since then, and the stock leapt by more than 8% after opening. Chief Executive Officer Flemming Ornskov said the firm's dermatological skincare and injectable aesthetics and in particular its therapeutic dermatology arms had all posted robust growth as Galderma continued to expand its market share. Ornskov was speaking to Reuters from Miami as the company establishes its new U.S. headquarters there, and he pointed to the growing importance of the United States, where Galderma generates more than 40% of its sales. "The U.S. is super important to us, and we continue to build out both our infrastructure and our manufacturing there," Ornskov said. Galderma said it saw as manageable its exposure to announced U.S. tariffs, which are fully factored-in for the full-year, and was confident that it could absorb some further tariff impact and consumer demand-related deterioration.
Yahoo
14-07-2025
- Business
- Yahoo
Analytics Equipment Maker Waters Buys Becton Dickinson Unit in a $17.5B Deal
Waters said it reached a deal to buy the Biosciences & Diagnostic Solutions business of Becton Dickinson for around $17.5 billion. The analytics instrument manufacturer said the acquisition would boost its market reach. The deal will leave Waters shareholders holding a 60.8% stake in the combined firm, with Becton Dickinson investors holding the other 39.2%.Waters (WAT) shares tumbled over 12% Monday morning after the analytics instruments maker said it plans to buy Becton Dickinson's (BDX) Biosciences & Diagnostic Solutions business in a Reverse Morris Trust transaction valued at $17.5 billion. Becton Dickinson shares were about 2% lower. Waters said the agreement will double its total addressable market for liquid chromatography, mass spectrometry, flow cytometry, and diagnostic solutions, as well as boost its recurring revenue, and provide other benefits. Chair Dr. Flemming Ornskov said as the board considered the merger, 'it became evident that combining with BD's Biosciences & Diagnostic Solutions business is an excellent strategic fit with complementary strengths.' He added that Waters believes the deal will 'accelerate our strategy in multiple high growth markets and deliver substantial near- and long-term value to our shareholders.' Under the terms of what is expected to be a tax-free transaction, Becton Dickinson's division will be spun off to its shareholders while simultaneously merged with a wholly-owned subsidiary of Waters. Waters investors will hold 60.8% of the combined firm, with Becton Dickinson shareholders the other 39.2%. It's anticipated to be completed in the first quarter of next year. Shares of Waters are down about 17% in 2025 so far, while Becton Dickinson shares have lost about a quarter of their value. Read the original article on Investopedia Sign in to access your portfolio
National Post
01-07-2025
- Business
- National Post
Galderma Announces Departure of Its Chief Financial Officer
Article content ZUG, Switzerland — Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that Thomas Dittrich, Chief Financial Officer, will be leaving the company to pursue another senior executive opportunity outside the organization. Article content 'We thank Thomas for his financial leadership and many contributions during his time at Galderma. He played a key role in establishing the financial discipline, operational readiness, and strategic clarity that will continue to guide us forward. We wish him every success in his next role and remain focused on further accelerating Galderma's strong growth – from category leadership to becoming a true powerhouse in dermatology.' FLEMMING ØRNSKOV, M.D., MPH CHIEF EXECUTIVE OFFICER GALDERMA Article content Thomas Dittrich will remain with the company as Chief Financial Officer through Q2 2026 to ensure a seamless transition through the close of the 2025 fiscal year. A successor will be announced in due course. Article content 'I want to thank Flemming, our Board of Directors, our investors, and all my colleagues at Galderma for their support throughout what has been the most impactful transformation and growth journey of my career. I leave holding Galderma in the highest regard, enormously proud of the strides we've made together, and equally excited about Galderma's continued growth momentum and long-term success.' THOMAS DITTRICH CHIEF FINANCIAL OFFICER GALDERMA Article content About Galderma Article content Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: Article content Forward-looking statements Article content Certain statements in this announcement are forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as 'plans', 'targets', 'aims', ' believes', 'expects', 'anticipates', 'intends', 'estimates', 'will', 'may', 'continues', 'should' and similar expressions. These forward-looking statements reflect, at the time, Galderma's beliefs, intentions and current targets/ aims concerning, among other things, Galderma's results of operations, financial condition, industry, liquidity, prospects, growth and strategies and are subject to change. The estimated financial information is based on management's current expectations and is subject to change. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which Galderma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Galderma's markets, and other factors beyond the control of Galderma). Neither Galderma nor any of their respective shareholders (as applicable), directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this announcement. Statements contained in this announcement regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. Some of the information presented herein is based on statements by third parties, and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, reasonableness, accuracy, completeness or correctness of this information or any other information or opinions contained herein, for any purpose whatsoever. Except as required by applicable law, Galderma has no intention or obligation to update, keep updated or revise this announcement or any parts thereof. Article content Article content Article content Article content Article content Contacts Article content For further information: Article content Christian Marcoux, Chief Communications Officer +41 76 315 26 50 Article content Richard Harbinson Corporate Communications Director +41 76 210 60 62 Article content Emil Ivanov Head of Strategy, Investor Relations, and ESG +41 21 642 78 12 Article content Article content Article content
Yahoo
01-07-2025
- Business
- Yahoo
Galderma Announces Departure of Its Chief Financial Officer
Ad hoc announcement pursuant to Art. 53 LR ZUG, Switzerland, July 01, 2025--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that Thomas Dittrich, Chief Financial Officer, will be leaving the company to pursue another senior executive opportunity outside the organization. "We thank Thomas for his financial leadership and many contributions during his time at Galderma. He played a key role in establishing the financial discipline, operational readiness, and strategic clarity that will continue to guide us forward. We wish him every success in his next role and remain focused on further accelerating Galderma's strong growth – from category leadership to becoming a true powerhouse in dermatology." FLEMMING ØRNSKOV, M.D., MPH CHIEF EXECUTIVE OFFICER GALDERMA Thomas Dittrich will remain with the company as Chief Financial Officer through Q2 2026 to ensure a seamless transition through the close of the 2025 fiscal year. A successor will be announced in due course. "I want to thank Flemming, our Board of Directors, our investors, and all my colleagues at Galderma for their support throughout what has been the most impactful transformation and growth journey of my career. I leave holding Galderma in the highest regard, enormously proud of the strides we've made together, and equally excited about Galderma's continued growth momentum and long-term success." THOMAS DITTRICH CHIEF FINANCIAL OFFICER GALDERMA About Galderma Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: Forward-looking statements Certain statements in this announcement are forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "plans", "targets", "aims", " believes", "expects", "anticipates", "intends", "estimates", "will", "may", "continues", "should" and similar expressions. These forward-looking statements reflect, at the time, Galderma's beliefs, intentions and current targets/ aims concerning, among other things, Galderma's results of operations, financial condition, industry, liquidity, prospects, growth and strategies and are subject to change. The estimated financial information is based on management's current expectations and is subject to change. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which Galderma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Galderma's markets, and other factors beyond the control of Galderma). Neither Galderma nor any of their respective shareholders (as applicable), directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this announcement. Statements contained in this announcement regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. Some of the information presented herein is based on statements by third parties, and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, reasonableness, accuracy, completeness or correctness of this information or any other information or opinions contained herein, for any purpose whatsoever. Except as required by applicable law, Galderma has no intention or obligation to update, keep updated or revise this announcement or any parts thereof. View source version on Contacts For further information: Christian Marcoux, Communications +41 76 315 26 50 Richard HarbinsonCorporate Communications +41 76 210 60 62 Emil IvanovHead of Strategy, Investor Relations, and +41 21 642 78 12 Jessica CohenInvestor Relations and Strategy +41 21 642 76 43
Yahoo
17-06-2025
- Business
- Yahoo
Galderma establishes new U.S. headquarters in Miami and strengthens regional leadership
Strategic move aims to accelerate innovation and growth in the U.S., Galderma's largest region MIAMI, June 17, 2025 /PRNewswire/ -- Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the establishment of its new U.S. headquarters in Miami, Florida, positioning the company at the heart of a thriving market for Dermatological Skincare and Injectable Aesthetics. Located in the vibrant Brickell neighborhood, the company expects to have approximately 150 employees, including U.S. leadership roles, based there by 2028. Miami's emergence as a premium market and destination for consumer skincare, consumer health, and aesthetic treatments aligns closely with Galderma's ambitions for its U.S. business, which is the company's largest region globally and a key driver of future growth. "Miami's creativity, energy and forward-thinking spirit are consistent with Galderma's ambitions. The city's emergence as a premium destination and a trend-setter in areas closely aligned to our activities, as well as its fast-growing healthcare professional community, makes Miami a natural choice for our U.S. headquarters. Being in Miami will enrich our business with top talent that will prove invaluable to our future success." FLEMMING ØRNSKOV, M.D., MPH CHIEF EXECUTIVE OFFICERGALDERMA The Miami metro area boasts one of the highest concentrations of medical spas and dermatological aesthetic clinics in the United States, with aesthetic procedures growing at an estimated 30% year-over-year. It also hosts the nation's second-largest medical district, the Miami Health District, with numerous hospitals and research facilities. With over 186,000 healthcare-related jobs and significant growth in startups, Florida is a hub for innovation in health and advanced medical technologies. Miami plays an important role in this ecosystem, with renowned research institutions and medical centers that house dedicated clinical teams focused on dermatology. "We are delighted to welcome Galderma to the Miami-Dade County area, which has witnessed considerable growth recently as companies increasingly find it to be an attractive location for investment. Miami-Dade has established itself as a key player in the life sciences and healthcare industry and having the pure-play dermatology industry leader anchor its U.S. business here will only bolster the region's reputation for innovation in this sector." RODRICK MILLERPRESIDENT AND CHIEF EXECUTIVE OFFICERMIAMI-DADE BEACON COUNCIL In addition to its new headquarters in Miami, Galderma will maintain a strong presence across several U.S. locations. Boston, MA, will remain the hub for the company's U.S. Therapeutic Dermatology business and U.S. Research and Development organization. Carlsbad, CA, will continue as a hub for Alastin®, the company's premium, physician-dispensed skincare brand. The Dallas, TX, office will continue as one of Galderma's key U.S. sites while the company's North America distribution center will remain in Fort Worth, TX. APPOINTING A NEW LEADER FOR GALDERMA has also announced today the appointment of Heather Wallace as President of Galderma U.S. Heather will be based in Miami. A proven senior business leader with deep expertise in dermatology and consumer health, she brings a strong track record of delivering commercial success and operational excellence. Heather previously led high-performing teams as Chief Executive Officer of Curology, the leader in personalized prescription skincare, and as President of the Americas region for Revlon, where she oversaw strategic and cultural transformation efforts to maximize profitability in the company's largest region. Her appointment signals Galderma's commitment to strengthening its U.S. leadership with forward-thinking talent capable of driving sustained growth in a dynamic and highly competitive landscape. GALDERMA'S LEADING PORTFOLIO OF PREMIUM BRANDSGalderma's synergistic portfolio of flagship brands holds leading market positions in Dermatological Skincare, Injectable Aesthetics, and Therapeutic Dermatology. In Dermatological Skincare, Galderma is best known for Cetaphil®, a leading dermatologist recommended brand for sensitive skin with more than 70-year heritage in the United States. Galderma's premium portfolio also includes the physician-dispensed skincare brand Alastin®, a leader in medical-grade peptide-based regenerative skincare. In Injectable Aesthetics, Galderma has a long history of aesthetics innovation and deep expertise in neuromodulators, as well as hyaluronic acid (HA) fillers and biostimulators. In Therapeutic Dermatology, Galderma brands hold leading positions in acne and rosacea and the company recently launched the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31 in prurigo nodularis and atopic dermatitis. ABOUT GALDERMAGalderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: For further information: Christian Marcoux, Chief Communications Officer +41 76 315 26 50 Jeffrey Smith Head of U.S. Communications +1 (682) 401-8428 Richard Harbinson Corporate Communications Director +41 76 210 60 62View original content to download multimedia: SOURCE Galderma
